糖皮质激素使用与类风湿关节炎患者高血压风险增加相关
结果显示近期使用糖皮质激素与高血压风险增加17%相关(HR 1.17,95%CI 1.10-1.24),且仅剂量高于7.5 mg时关联显著。
要点
- 近期使用糖皮质激素与类风湿关节炎患者高血压风险增加17%相关。
- 仅剂量高于7.5 mg的糖皮质激素与高血压风险显著相关。
- 临床处方糖皮质激素时应考虑心血管风险并定期监测血压。
核心结论
- 近期使用糖皮质激素与类风湿关节炎患者新发高血压相关,尤其是剂量≥7.5 mg时。
主要发现
- 随访期间7421例(42%)患者被处方糖皮质激素,高血压发病率为64.1/1000人年(95%CI 62.5-65.7)。
- 近期使用糖皮质激素与高血压风险增加17%相关(HR 1.17,95%CI 1.10-1.24)。
- 按剂量分类,仅剂量高于7.5 mg的糖皮质激素与高血压风险显著相关。
- 累积剂量未显示与高血压风险存在明确模式。
关键数值与推荐
- 高血压定义为血压测量>140/90 mmHg,或使用降压药并有高血压Read代码。
- 糖皮质激素使用采用3个月归因窗口判定近期使用、剂量和累积剂量。
临床怎么用
- 临床医生为类风湿关节炎患者处方糖皮质激素时应考虑心血管风险,并确保定期监测血压,必要时予以治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with RA are frequently treated with glucocorticoids (GCs), but evidence is conflicting about whether GCs are associated with hypertension. The aim of this study was to determine whether GCs are associated with incident hypertension in patients with RA. METHODS: A retrospective cohort of patients with incident RA and without hypertension was identified from UK primary care electronic medical records (Clinical Practice Research Datalink). GC prescriptions were used to determine time-varying GC use, dose and cumulative dose, with a 3 month attribution window. Hypertension was identified through either: blood pressure measurements >140/90 mmHg, or antihypertensive prescriptions and a Read code for hypertension. Unadjusted and adjusted Cox proportional hazards regression models were fitted to determine whether there was an association between GC use and incident hypertension. RESULTS: There were 17 760 patients in the cohort. A total of 7421 (42%) were prescribed GCs during follow-up. The incident rate of hypertension was 64.1 per 1000 person years (95% CI: 62.5, 65.7). The Cox proportional hazards model indicated that recent GC use was associated with a 17% increased hazard of hypertension (hazard ratio 1.17; 95% CI: 1.10, 1.24). When categorized by dose, only doses above 7.5 mg were significantly associated with hypertension. Cumulative dose did not indicate a clear pattern. CONCLUSION: Recent GC use was associated with incident hypertension in patients with RA, in particular doses ≥7.5 mg were associated with hypertension. Clinicians need to consider cardiovascular risk when prescribing GCs, and ensure blood pressure is regularly monitored and treated where necessary.
引用
- Costello RE, Yimer BB, Roads P, et al. Glucocorticoid use is associated with an increased risk of hypertension. Rheumatology (Oxford). 2021. PMID: 32596721. doi:10.1093/rheumatology/keaa209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。